ReviewPharmaceutics2020
Mesoporous Silica Nanoparticles as Theranostic Antitumoral Nanomedicines.
Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Nanomaterial-Based Therapeutic Delivery: Integrating Redox Biology, Genetic Engineering, and Imaging-Guided Treatment.Antioxidants (Basel, Switzerland) · 2026Review
- Nanoparticles and Nanomaterials: A Review from the Standpoint of Pharmacy and Medicine.Pharmaceutics · 2025Review
- Smart Ultrasound-responsive Polymers for Drug Delivery: An Overview on Advanced Stimuli-sensitive Materials and Techniques.Current drug delivery · 2025Review
- Role of physicochemical properties in silica nanoparticle-mediated immunostimulation.Nanotoxicology · 2024Article
- Nanomedicine for cancer patient-centered care.MedComm · 2024Review
- Modification of Silica with Sucrose and Ammonium Fluoride Agents: A Facile Route to Prepare Supports of Iridium Catalysts for Hydrogenation Reaction.Molecules (Basel, Switzerland) · 2024Article
- An Overview of Current Progress and Challenges in Brain Cancer Therapy Using Advanced Nanoparticles.Recent patents on nanotechnology · 2024Review
- Mesoporous Silica Nanoparticles: Types, Synthesis, Role in the Treatment of Alzheimer's Disease, and Other Applications.Pharmaceutics · 2023Review
- Localized Therapeutic Approaches Based on Micro/Nanofibers for Cancer Treatment.Molecules (Basel, Switzerland) · 2023Review
- Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?Chemical Society reviews · 2022Review
- Bacteria and cells as alternative nano-carriers for biomedical applications.Expert opinion on drug delivery · 2022Review
- Costunolide Loaded in pH-Responsive Mesoporous Silica Nanoparticles for Increased Stability and an Enhanced Anti-Fibrotic Effect.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Hard and Soft Protein Corona of Nanomaterials: Analysis and Relevance.Nanomaterials (Basel, Switzerland) · 2021Review
- Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases.Cells · 2021Review
- Novel IMB16-4 Compound Loaded into Silica Nanoparticles Exhibits Enhanced Oral Bioavailability and Increased Anti-Liver Fibrosis In Vitro.Molecules (Basel, Switzerland) · 2021Article
- Development of Non-Porous Silica Nanoparticles towards Cancer Photo-Theranostics.Biomedicines · 2021Review
- Nanomaterials for Ultrasound Imaging- Guided Sonodynamic Therapy.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nanoparticles have become a powerful tool in oncology not only as carrier of the highly toxic chemotherapeutic drugs but also as imaging contrast agents that provide valuable information about the state of the disease and its progression. The enhanced permeation and retention effect for loaded nanocarriers in tumors allow substantial improvement of selectivity and safety of anticancer nanomedicines. Additionally, the possibility to design stimuli-responsive nanocarriers able to release their payload in response to specific stimuli provide an excellent control on the administered dosage. The aim of this review is not to present a comprehensive revision of the different theranostic mesoporous silica nanoparticles (MSN) which have been published in the recent years but just to describe a few selected examples to offer a panoramic view to the reader about the suitability and effectiveness of these nanocarriers in the oncology field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.